Octreotide medicine rebate agreement

Summary

The tender concerns the conclusion of a non-exclusive rebate agreement for medicines containing octreotide between DAK-Gesundheit and interested pharmaceutical companies. The agreement is intended to cover medicines dispensed at the expense of statutory health insurance funds for the period 1 July 2026 to 30 June 2028, with an option to extend once for 12 months. The machine-readable notice did not include precise qualification, exclusion or compliance requirements; these must be checked in the tender documents.